Evidence map›Paper›PMID 32639484›Full record

ArticleEClinicalMedicine2020

The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial.

Erika S Levy, Gemma Moya-Galé, Young Hwa M Chang, Katherine Freeman, Karen Forrest, Mitchell F Brin, Lorraine A Ramig

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Community-Supported Shared Infrastructure in Support of Speech Accessibility.Journal of speech, language, and hearing research : JSLHR · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Sex Differences in the Speech of Persons With and Without Parkinson's Disease.American journal of speech-language pathology · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Erika S LevyDepartment of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, United States.
Gemma Moya-GaléDepartment of Communication Sciences and Disorders, Long Island University, Brooklyn, NY, United States.
Young Hwa M ChangDepartment of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, United States.
Katherine FreemanDepartment of Biomedical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States.
Karen ForrestDepartment of Speech and Hearing Sciences, Indiana University, Bloomington, IN, United States.
Mitchell F BrinDepartment of Neurology, University of California, Irvine, Allergan LLC, Irvine, CA, United States.
Lorraine A RamigDepartment of Biobehavioral Sciences, Teachers College, Columbia University, New York, NY, United States.
Columbia University · USFlorida Atlantic University · USIndiana University Bloomington · USLong Island University · USUniversity of California, Irvine · USUniversity of Colorado Boulder · US

Funding

Information Processing &the Inferior ColliculusR01DC000115 · NIDCD · JOHNS HOPKINS UNIVERSITY · PI ZHANG, KECHEN · 1989 to 2014
$6.4M
NIDCD NIH HHS R01 DC000115
6 · The paper itself

Abstract

backgroundMore than 6,000,000 individuals worldwide are diagnosed with Parkinson's disease (PD). Nearly 90% develop speech signs that may substantially impair their speech intelligibility, resulting in losses in their communication and quality of life. Benefits of intensive speech treatment have been documented for a range of speech signs. However, the critical question of whether speech is more intelligible after treatment has not been investigated in a randomised controlled trial (RCT). We hypothesised that intensive speech treatment would improve speech intelligibility in PD.

methodSixty-four patients with hypokinetic dysarthria secondary to PD participated in this single-centre, parallel arm, statistically-powered RCT. Reporting follows CONSORT guidelines for non-pharmacological treatment. Patients were recruited from US clinics and randomised using a statistician-derived minimisation algorithm, to intensive speech treatment (16 1-hour sessions/1 month) targeting voice (voice group) or targeting articulation (articulation group) or to an untreated group (no treatment group). Speech treatments were delivered by speech clinicians who specialised in treating patients with PD. Trial design minimised bias and supported equipoise. For intelligibility assessment, blinded listeners (

findingsBetween June 23, 2016 and August 14, 2017, blinded listeners transcribed baseline and post-treatment speech samples for intelligibility assessment of 57 patients in the voice (

interpretationThese findings provide the first RCT evidence that intensive speech treatment targeting voice improves speech intelligibility in PD. Thus, this evidence-based treatment may positively impact health-related quality of life for patients with PD globally when it is included in patient management.

funding

Indexed as

DysarthriaIntelligibilityParkinson's diseaseRCTSpeech treatment

Identifiers

PMID32639484
PMCPMC7327886
OpenAlexW3037845634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.